⁹⁰Y-Besilesomab is the therapeutic analogue of the ^99mTc-labeled murine anti-granulocyte mAb BW250/183 available under the trade name Scintimun®. This molecule is developed as a therapeutic agent for the treatment of systemic amyloid light chain amyloidosis (SALA) using the companion diagnostic agent ¹¹¹In-Besilesomab. ⁹⁰Y-besilesomab has been granted orphan drug designation status in Europe for the broad indication of Bone Marrow Conditioning (BMC) for Hematopoietic Stem Cell Transplantation (HSCT).

The antibody is targeting CD66 and the ⁹⁰Y-labeled form is now evaluated in patients affected by amyloidosis on the basis of a SPECT confirmation of the presence of the disease with the ¹¹¹In-analogue (Phase I/II).

Target/Mechanism: CD66

Carrier/Ligand: Besilesomab

Radiation Type: beta electrons (β^–)